Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155

D. W. Lee, M. Futami, M. Carroll, Y. Feng, Z. Wang, M. Fernandez, Z. Whichard, Y. Chen, S. Kornblau, E. J. Shpall, C. E. Bueso-Ramos, S. J. Corey*

*Corresponding author for this work

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

The myelodysplastic syndromes (MDSs) comprise a group of disorders characterized by multistage progression from cytopenias to acute myeloid leukemia (AML). They display exaggerated apoptosis in early stages, but lose this behavior during evolution to AML. The molecular basis for loss of apoptosis is unknown. To investigate this critical event, we analyzed phosphatidylinositol (PI) 3′kinase signaling, implicated as a critical pathway of cell survival control in epithelial and hematological malignancies. PI 3′kinase activates Akt through its production of 3′ phosphoinositides. In turn, the phosphoinositides are dephosphorylated by two lipid phosphatases, PTEN and SHIP-1, in myeloid cells. We studied primary MDS-enriched bone marrow cells and bone marrow sections by western blotting, immunohistochemistry, immunocytochemistry and quantitative PCR for components of the SHIP/PTEN/PI 3′kinase signaling circuit. We reported constitutively activated Akt, variable levels of PTEN and uniformly decreased SHIP-1 expression in MDS progenitor cells. Overexpression of SHIP-1, but not the phosphatase-deficient form, inhibited myeloid leukemic growth. Levels of microRNA (miR)-210 and miR-155 transcripts, which target SHIP-1, were increased in CD34 MDS cells compared with their normal counterparts. Direct binding of miR-210 to the 3′ untranslated region of SHIP-1 was confirmed by luciferase reporter assay. Transfection of a myeloid cell line with miR-210 resulted in loss of SHIP-1 protein expression. These data suggest that miR-155 and miR-210/SHIP-1/Akt pathways could serve as clinical biomarkers for disease progression, and that miR-155 and miR-210 might serve as novel therapeutic targets in MDS.

Original languageEnglish (US)
Pages (from-to)4085-4094
Number of pages10
JournalOncogene
Volume31
Issue number37
DOIs
StatePublished - Sep 1 2012

Keywords

  • Akt
  • SHIP-1
  • leukemia

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155'. Together they form a unique fingerprint.

  • Cite this

    Lee, D. W., Futami, M., Carroll, M., Feng, Y., Wang, Z., Fernandez, M., Whichard, Z., Chen, Y., Kornblau, S., Shpall, E. J., Bueso-Ramos, C. E., & Corey, S. J. (2012). Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene, 31(37), 4085-4094. https://doi.org/10.1038/onc.2011.579